A system for the synthesis of ferrocene nanoparticles for targeted breast cancer therapy

The anti-solvent precipitation technique enables efficient and cost-effective synthesis of ferrocene nanoparticles with controlled properties, addressing scalability and biological applicability issues, showing promising anti-cancer efficacy against breast cancer cells.

DE202024106725U1Active Publication Date: 2025-01-16DANDGE PRAFULL BABULAL KOLHAPUR +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE202024106725
Authority / Receiving Office
DE · DE
Patent Type
Utility models
Current Assignee / Owner
Filing Date
2024-11-21
Publication Date
2025-01-16
Estimated Expiration
2034-11-30

AI Technical Summary

Technical Problem

Current methods for synthesizing ferrocene nanoparticles are complex, energy-intensive, and often use harsh conditions or toxic reagents, limiting their scalability and biological applicability for targeted cancer treatment.

Method used

A system using anti-solvent precipitation technique to synthesize ferrocene nanoparticles, involving a reactor assembly with a dissolution chamber, precipitation chamber, stirring module, centrifuge unit, and drying module, allowing precise control over particle properties without specialized equipment.

Benefits of technology

The system produces high-purity ferrocene nanoparticles with controlled properties, demonstrating significant anti-cancer activity against breast cancer cells, with improved scalability and reduced production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

A system (100) for synthesizing ferrocene nanoparticles (FcNPs) for targeted breast cancer therapy, comprising: a reactor arrangement (102) for synthesizing FcNPs, wherein the reactor arrangement comprises: i) a dissolution chamber (104) configured to contain a precursor solution of ferrocene and acetonitrile; ii) a precipitation chamber (106) containing deionized water; iii) a stirring module (108) connected to the precipitation chamber (106) and configured for operation at 1000 rpm, wherein the stirring module (108) continuously stirs the deionized water; iv) a microsyringe device (110) connected to the dissolution chamber (104) and configured to inject the precursor solution into the precipitation chamber (106) to obtain a ferrocene nanosuspension; v) a centrifuge unit (112) configured for operation at 5000 rpm for centrifuging the ferrocene nanosuspension; vi) a collection unit (114) comprising a means for separating (114a) the FcNPs nanoparticles from the centrifugation unit (112); and vii) a staining module (116) comprising a hot air oven (116a) configured to dry the separated FcNPs.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The present disclosure relates to a system for the synthesis of ferrocene nanoparticles for targeted breast cancer therapy, in particular a system for the synthesis of ferrocene nanoparticles by antisolvent precipitation and performing an in vitro cytotoxicity screening of the synthesized nanoparticles on the breast cancer cell line (MCF-7). BACKGROUND OF THE INVENTION

[0002] Metal-based nanoparticles have proven to be important therapeutic agents in modern medicine, particularly in oncology. While conventional cancer treatments face challenges such as drug resistance and non-specific targeting, organometallic compounds, especially metallocenes, offer a potential solution due to their unique structural and electrochemical properties. Among them, ferrocene, the archetypal metallocene, exhibits remarkable properties, including reversible redox behavior, thermal stability, and biocompatibility, making it particularly suitable for therapeutic applications.

[0003] Despite the recognized potential of ferrocene in medicinal chemistry, as demonstrated by successful derivatives such as ferroquine and ferrocifene, its application in nanostructured form remains largely unexplored. Current synthesis techniques or systems for organic nanomaterials, including self-assembly, microemulsion, and layer-by-layer assembly, often require complex processing conditions, high energy input, and sophisticated equipment, and frequently involve high-speed shear mixing, ultrasonic treatment, or specialized templates, resulting in higher production costs and reduced scalability.

[0004] Existing systems for the synthesis of ferrocene nanoparticles are limited by their complexity, energy requirements, and potential for particle aggregation.

[0005] These limitations have hampered the development and evaluation of ferrocene nanostructures for therapeutic applications, particularly for targeted cancer treatment. Furthermore, conventional synthesis techniques often involve harsh conditions or toxic reagents, which can impair the biological applicability of the resulting nanoparticles.

[0006] To address the aforementioned challenges, the present invention provides a system for the synthesis of ferrocene nanoparticles for targeted breast cancer therapy. This system is an efficient, cost-effective synthesis system for ferrocene nanoparticles that allows precise control over the particle properties while eliminating the need for complex processing conditions or specialized equipment. SUMMARY OF THE INVENTION

[0007] This disclosure concerns a system for the synthesis of ferrocene nanoparticles for targeted breast cancer therapy. The proposed system uses an anti-solvent precipitation technique to produce ferrocene nanoparticles (FcNPs). The ferrocene is first dissolved in acetonitrile (5 mg mL) -1)The precursor solution (20 ml) is dissolved in a precursor solution. This precursor solution is then injected into deionized water (200 ml) using a microsyringe, with the water being stirred at a continuous speed of 1000 rpm. Mixing the precursor solution in the deionized water results in a ferrocene nanosuspension. The resulting nanosuspension is centrifuged at 5000 rpm for 15 minutes. The precipitated nanoparticles are separated and then dried in a hot air oven for 12 hours. The prepared nanoparticles are characterized and subsequently subjected to in vitro cytotoxicity screening using the breast cancer cell line (MCF-7).

[0008] The present disclosure is intended to provide a system for the synthesis of ferrocene nanoparticles for targeted breast cancer therapy. The system comprises: a reactor arrangement for the synthesis of FcNPs, wherein the reactor arrangement includes: a dissolution chamber configured to contain a precursor solution of ferrocene and acetonitrile; a precipitation chamber containing deionized water; a stirring module connected to the precipitation chamber and configured to operate at 1000 rpm, the stirring module continuously stirring the deionized water; a microsyringe device connected to the dissolution chamber and configured to inject the precursor solution into the precipitation chamber to obtain a ferrocene nanosuspension; and a centrifuge unit configured to operate at 5000 rpm to centrifuge the ferrocene nanosuspension.a collection unit comprising a means for separating the FcNP nanoparticles from the centrifuge unit; and a staining module comprising a hot air oven configured for drying the separated FcNPs.

[0009] In one embodiment, the solution chamber comprises: i) a temperature control module; ii) a concentration monitoring unit; and iii) a mixing device configured to ensure complete dissolution of ferrocene in acetonitrile.

[0010] In one embodiment, the dissolution chamber includes a concentration control unit configured to measure the ferrocene concentration in acetonitrile at 5 mg mL -1 to keep.

[0011] In one embodiment, the microsyringe device is configured to maintain a specific volume ratio between ferrocene solution and deionized water.

[0012] In one embodiment, the centrifuge unit includes a timer module configured for 15 minutes of operation.

[0013] In one embodiment, the hot air oven includes a timer module configured for 12 hours of operation.

[0014] In one embodiment, the manufactured ferrocene nanoparticles are subjected to in vitro cell cytotoxicity screening on the breast cancer cell line (MCF-7) by performing a 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) test.

[0015] One objective of this disclosure is to provide a system for the synthesis of ferrocene nanoparticles for targeted breast cancer therapy.

[0016] Another objective of this disclosure is the synthesis of ferrocene nanoparticles by using anti-solvent precipitation technology.

[0017] Another objective of this disclosure is to characterize the manufactured nanoparticles by using a variety of characterization tools.

[0018] Another objective of this disclosure is to conduct an in vitro cytotoxicity screening of the manufactured nanoparticles on the breast cancer cell line (MCF-7).

[0019] Another objective of this disclosure is to provide nanoparticles for the treatment of breast cancer.

[0020] To further clarify the advantages and features of the present disclosure, a more detailed description of the invention is given with reference to specific embodiments thereof, which are illustrated in the accompanying drawings. It should be noted that these drawings represent only typical embodiments of the invention and are therefore not to be considered as limiting its scope. The invention is described and explained with additional details and information with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE CHARACTERS

[0021] These and other features, aspects, and benefits of this disclosure will be better understood when the following detailed description is read with reference to the accompanying drawings, in which identical symbols consistently represent identical parts. The following applies: Fig. Figure 1 shows a block diagram of a system for the synthesis of ferrocene nanoparticles (FcNPs) for targeted breast cancer therapy according to an embodiment of the present disclosure; Fig. Figure 2 shows a graphical representation of the XRD analysis of synthesized a) FcNPs and b) bare ferrocene according to an embodiment of the present disclosure; Fig. Figure 3 shows a graphical representation of an FT-IR analysis of a) FcNPs and b) bare ferrocene according to an embodiment of the present disclosure.

[0022] Furthermore, those skilled in the art will recognize that elements in the drawings are presented for the sake of simplicity and are not necessarily drawn to scale. For example, the flowcharts illustrate the method by outlining the main steps to enhance understanding of aspects of this disclosure. Additionally, with regard to the design of the device, one or more components of the device may be represented in the drawings by conventional symbols, and the drawings may show only the specific details relevant to understanding the embodiments of this disclosure, so as not to clutter the drawings with details that are readily apparent to those skilled in the art who benefit from the description herein. DETAILED DESCRIPTION:

[0023] To facilitate an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and described in specific language. It is to be understood, however, that this is not intended to limit the scope of the invention, as such changes and further modifications to the illustrated system and such further applications of the principles of the invention as illustrated therein are contemplated as would normally occur to one skilled in the art to which the invention pertains.

[0024] It will be understood by one skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting thereof.

[0025] References in this specification to "one aspect," "another aspect," or similar language mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Therefore, occurrences of the phrase "in one embodiment," "in another embodiment," and similar language throughout this specification may or may not all refer to the same embodiment.

[0026] The terms "comprises," "comprising," or other variations thereof are intended to cover non-exclusive inclusion, such that a process or method comprising a list of steps not only includes those steps, but may also include other steps not expressly listed or inherent in such process or method. Likewise, one or more devices or subsystems or elements or structures or components preceded by "comprises...a" does not preclude, without further limitation, the existence of other devices or other subsystems or other elements or other structures or other components or additional devices or additional subsystems or additional elements or additional structures or additional components.

[0027] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The system, methods, and examples provided herein are for illustrative purposes only and should not be considered limiting.

[0028] Embodiments of the present disclosure are described in detail below with reference to the accompanying drawings.

[0029] Fig. Figure 1 shows a block diagram of a system (100) for the synthesis of ferrocene nanoparticles (FcNPs) for targeted breast cancer therapy according to an embodiment of the present disclosure.

[0030] With reference to Fig. 1 The system (100) comprises: a reactor arrangement (102) for synthesizing FcNPs, the reactor arrangement (102) comprising: a solution chamber (104) configured to contain a precursor solution of ferrocene and acetonitrile; a precipitation chamber (106) containing deionized water; a stirring module (108) connected to the precipitation chamber (106) and configured for operation at 1000 rpm, the stirring module (108) continuously stirring the deionized water; a microsyringe device (110) connected to the solution chamber (104) and configured for injecting the precursor solution into the precipitation chamber (106) to obtain a ferrocene nanosuspension; a centrifuge unit (112) configured for operation at 5000 rpm to centrifuge the ferrocene nanosuspension;a collection unit (114) comprising a means for separating (114a) the FcNPs nanoparticles from the centrifuge unit (112); and a staining module (116) comprising a hot air oven (116a) configured for drying the separated FcNPs.

[0031] In one embodiment, the solution chamber comprises: i) a temperature control module (104a); ii) a concentration monitoring unit (104b); and iii) a mixing device (104c) configured to ensure complete dissolution of ferrocene in acetonitrile.

[0032] In one embodiment, the dissolution chamber (104) comprises a concentration control unit (104d) configured to control the ferrocene concentration in acetonitrile at 5 mg mL -1 to keep

[0033] In one embodiment, the microsyringe device (110) is configured to maintain a specific volume ratio between ferrocene solution and deionized water.

[0034] In one embodiment, the centrifuge unit (112) includes a timer module (112a) configured for operation for 15 minutes.

[0035] In one embodiment, the hot air oven (116a) includes a timer module (116b) configured for 12 hours of operation.

[0036] In one embodiment, the manufactured ferrocene nanoparticles are subjected to in vitro cell cytotoxicity screening on the breast cancer cell line (MCF-7) by performing a 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) test.

[0037] The present invention relates to a system for the synthesis of ferrocene nanoparticles using an anti-solvent precipitation technique. First, ferrocene was used as a precursor solution in acetonitrile (5 mg mL). - 1) dissolved. In the next step, the ferrocene solution (20 mL) was injected into deionized water (200 mL) using a microsyringe while stirring continuously (1000 rpm). The ferrocene nanosuspension was then centrifuged for 15 minutes at 5000 rpm. Finally, the FcNPs were separated and dried in a hot air oven for 12 hours.

[0038] The synthesized nanoparticles were subjected to in vitro cytotoxicity screening using the breast cancer cell line (MCF-7). The cytotoxicity of the FcNPs was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using the breast cancer cell line (MCF-7) with minor modifications. The respective cell lines were classified as 10 5Cells were seeded per well in 100 µL of culture medium in 96-well microplates (tissue culture grade). A test sample of FcNPs was then incubated for 24 hours at 37 °C with 5% CO2 in a CO2 incubator at varying concentrations (20, 40, 60, 80, 100 µg / mL). The control was prepared by incubating the cell lines with DMSO (0.2%) in phosphate buffer (PBS) and incubated in triplicate. The control was also retained to monitor cell survival and the percentage of viable cells after culture. After incubation, the medium was completely aspirated, and then 20 µL of MTT reagent (5 mg / mL in PBS) was added to each well. The cells were then incubated for a further 4 hours at 37 °C in a CO2 incubator.The yellowish MTT was reduced to a dark-stained formazan exclusively by viable cells, and the formation of formazan crystals in the wells was observed under a microscope. Subsequently, after complete removal of the incubation medium, 200 µl of DMSO were added and the sample was incubated for 10 minutes at 37 °C. The absorbance of each sample was measured at 550 nm using a microplate reader. Cell viability was calculated as a percentage compared to the blank value. %Inhibition=[(AC−AS) / AC]∗100 where, AC = Absorption of Control AS = absorbance of sample / standard.

[0039] The anti-solvent precipitation method, with modifications, has been used for the efficient synthesis of ferrocene nanoparticles (FcNPs). By introducing hydrophobic ferrocene, dissolved in acetonitrile (the good solvent), into a large volume of a poor solvent, particularly deionized (DI) water, the solution reaches supersaturation, causing ferrocene to precipitate in the distilled water and forming a dispersion of FcNPs. The formation mechanism of FcNPs involves nucleation, in which microscopic, unstable (subcritical) nuclei or "seeds" dynamically evolve into metastable (supercritical) FcNPs through heterogeneous nucleation occurring at points of structural inhomogeneity.

[0040] Fig. Figure 2 shows a graphical representation of the XRD analysis of synthesized a) FcNPs and b) bare ferrocene according to an embodiment of the present disclosure.

[0041] XRD analysis was used to investigate the crystal structure and diffraction pattern of FcNPs.

[0042] With reference to Fig. X-ray diffraction (XRD) analysis shows planes at (110), (001), (201), (111), (200), (211), and (210) with 20-degree values ​​of 15.5, 17.39, 18.27, 18.89, 19.60, 21.68, and 22.73, respectively, indicating a high degree of crystallinity and a monoclinic phase of ferrocene (JCPDS No. 29-1711), revealing a high purity. The XRD pattern of bare ferrocene and FcNPs showed no change in the monoclinic phase, indicating no change in phase crystallinity. The crystal size of the synthesized FcNPs was calculated to be 9 nm using the Debye-Scherrer equation.

[0043] Fig. Figure 3 shows a graphical representation of an FT-IR analysis of a) FcNPs and b) bare ferrocene according to an embodiment of the present disclosure.

[0044] In relation to Fig. The formation of FcNPs was further confirmed by FT-IR spectroscopy, in which the spectrum showed a peak at 3090 cm⁻¹. -1 showed, which is assigned to the aromatic CH stretching vibrations of the cyclopentadienyl ring of ferrocene. The characteristic peaks of ferrocene were similarly observed for FcNPs at 482.78 cm⁻¹. -1, 814.36 cm -1, 999.62 cm -1, 1102.20 cm -1 and 1054.74 cm -1 The FT-IR peaks of the FcNPs and the ferrocene bulk material were observed to be identical, indicating that no changes occurred during the formation of the FcNPs.

[0045] Additionally, the hydrodynamic size and colloidal stability of FcNPs in aqueous dispersion were evaluated using dynamic light scattering (DLS). DLS analysis revealed a Z-average size of 128.3 nm (PDI of 0.508) and a zeta potential of -23.5 mV. The narrow size distribution and high zeta potential of FcNPs are attributed to their superior colloidal stability in aqueous dispersion, suggesting their suitability for various therapeutic strategies.

[0046] The TEM was recorded at high resolution and revealed the internal morphology of the FcNPs. TEM micrographs of the FcNPs showed that the polycrystalline form appeared as clusters with an average particle size of 32 ± 0.5 nm. The ring pattern with bright circular spots in the SAED pattern confirms a high crystallinity corresponding to the lattice planes, which is consistent with the XRD pattern of the FcNPs.

[0047] To evaluate the anticancer activity of the synthesized nanoparticles, the in vitro cytotoxicity of FcNPs was assessed in the present invention using the 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay on the breast cancer cell line MCF-7 with FcNP concentrations of 20 to 100 µg / ml. The MTT assay showed a dose-dependent reduction in the cell viability of the breast cancer cell line MCF-7 after treatment with FcNPs. Furthermore, FcNPs exhibited significant anticancer effects on the breast cancer cell line MCF-7, with a significant reduction in cell viability to 59.96% at a concentration of 100 µg / ml and an IC50 of 100%. 50- A value of 82.21 µg / ml compared to the standard drug 5-fluorouracil, which has an IC50 50 of 45.48 µg / ml. These results underscore the promising anticancer potential of FcNPs, particularly against breast cancer.

[0048] Spectrochemical characterization revealed no changes in the structure of ferrocene, indicating high purity of the synthesized FcNPs. Furthermore, the results of the anticancer activity analysis showed significant anticancer activity of the FcNPs against breast cancer (MCF-7). Due to its straightforward structure, ease of handling, high efficiency, and flexibility for controlled reactions, the approach provided in the present invention could be applied to the synthesis of other organometallic nanoparticles.

[0049] The drawings and the preceding description provide examples of embodiments. Those skilled in the art will recognize that one or more of the described elements can be combined to form a single functional element. Alternatively, certain elements can be divided into several functional elements. Elements from one embodiment can be added to another embodiment. For example, the sequences of the processes described herein can be changed and are not limited to the manner described herein. Furthermore, the actions of any flowchart need not be implemented in the sequence shown; nor do all actions necessarily need to be performed. Actions that are not dependent on other actions can also be performed in parallel with the other actions. The scope of embodiments is in no way limited by these specific examples.Numerous variations, whether explicitly stated in the specification or not, such as differences in structure, dimensions, and material use, are possible. The scope of the embodiments is at least as broad as indicated in the following claims.

[0050] Advantages, other benefits, and solutions to problems have been described above with reference to specific embodiments. However, the advantages, benefits, solutions to problems, and any components that may cause an advantage or solution to occur or become more apparent are not to be construed as a critical, required, or essential feature or component of any or all of the claims. REFERENCE 100 A system for the synthesis of ferrocene nanoparticles (FcNPs) for targeted breast cancer therapy. 102 Reactor assembly 104 Dissolution Chamber 104a Temperature control module 104b Concentration monitoring unit 104c Mixing apparatus 104d Concentration Control Unit 106 Precipitation chamber 108 Stirring module 110 microsyringe apparatus 112 centrifuge units 112a Timer module 114 Collection Unit 114a Means of separation 116 Staining module 116a Hot air oven 116b Timer module

Claims

[1] A system (100) for synthesizing ferrocene nanoparticles (FcNPs) for targeted breast cancer therapy, comprising: a reactor assembly (102) for synthesizing FcNPs, the reactor assembly comprising: i) a dissolution chamber (104) configured to contain a precursor solution of ferrocene and acetonitrile; ii) a precipitation chamber (106) containing deionised water; iii) a stirring module (108) connected to the precipitation chamber (106) and configured to operate at 1000 rpm, the stirring module (108) continuously stirring the deionized water; iv) a microsyringe device (110) connected to the dissolution chamber (104) and configured to inject the precursor solution into the deposition chamber (106) to obtain a nanosuspension of ferrocene; v) a centrifuge unit (112) configured to operate at 5000 rpm for centrifuging the ferrocene nanosuspension; vi) a collection unit (114) comprising a means for separating (114a) the FcNPs nanoparticles from the centrifugation unit (112); and vii) a staining module (116) comprising a hot air oven (116a) configured to dry the separated FcNPs. [2] The system of claim 1, wherein the dissolution chamber comprises: i) a temperature control module (104a); ii) a concentration monitoring unit (104b); and iii) a mixing device (104c) configured to ensure complete dissolution of ferrocene in acetonitrile. [3] The system according to claim 1, wherein the dissolution chamber (104) comprises a concentration control unit (104d) configured to maintain the ferrocene concentration in acetonitrile at 5 mg mL -1 to keep. [4] The system of claim 1, wherein the microsyringe device (110) is configured to maintain a specific volume ratio between ferrocene solution and deionized water. [5] The system of claim 1, wherein the centrifuge unit (112) includes a timer module (112a) configured for 15 minutes of operation. [6] The system of claim 1, wherein the convection oven (116a) includes a timer module (116b) configured for 12 hours of operation. [7] The system according to claim 1, wherein the prepared ferrocene nanoparticles are subjected to in vitro cell cytotoxicity screening on the breast cancer cell line (MCF-7) by performing a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.